• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

α-1-油酸治疗膀胱癌患者的临床和分子反应。

Clinical and molecular response to alpha1-oleate treatment in patients with bladder cancer.

机构信息

Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Sweden.

Department of Pathology and Molecular Medicine, Motol University Hospital, 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic.

出版信息

Cancer Med. 2024 Sep;13(17):e70149. doi: 10.1002/cam4.70149.

DOI:10.1002/cam4.70149
PMID:39254154
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11386334/
Abstract

BACKGROUND

The tumoricidal complex alpha1-oleate targets bladder cancer cells, triggering rapid, apoptosis-like tumor cell death. Clinical effects of alpha1-oleate were recently observed in patients with non-muscle invasive bladder cancer (NMIBC), using a randomized, placebo-controlled study protocol.

AIMS

To investigate if there are dose-dependent effects of alpha1-oleate.

MATERIALS AND METHODS

Here, patients with NMIBC were treated by intravesical instillation of increasing concentrations of alpha1-oleate (1.7, 8.5, or 17 mM) and the treatment response was defined relative to a placebo group.

RESULTS

Strong, dose-dependent anti-tumor effects were detected in alpha1-oleate treated patients for a combination of molecular and clinical indicators; a complete or partial response was detected in 88% of tumors treated with 8.5 mM compared to 47% of tumors treated with 1.7 mM of alpha1-oleate. Uptake of alpha1-oleate by the tumor triggered rapid shedding of tumor cells into the urine and cell death by an apoptosis-like mechanism. RNA sequencing of tissue biopsies confirmed the activation of apoptotic cell death and strong inhibition of cancer gene networks, including bladder cancer related genes. Drug-related side effects were not recorded, except for local irritation at the site of instillation.

DISCUSSION AND CONCLUSIONS

These dose-dependent anti-tumor effects of alpha1-oleate are promising and support the potential of alpha1-oleate treatment in patients with NMIBC.

摘要

背景

杀肿瘤复合物α1-油酸靶向膀胱癌细胞，引发快速、类似凋亡的肿瘤细胞死亡。最近在非肌肉浸润性膀胱癌（NMIBC）患者中使用随机、安慰剂对照研究方案观察到了α1-油酸的临床效果。

目的

研究α1-油酸是否存在剂量依赖性效应。

材料和方法

在这里，NMIBC 患者通过膀胱内灌注不同浓度的α1-油酸（1.7、8.5 或 17mM）进行治疗，并将治疗反应与安慰剂组进行比较。

结果

在接受α1-油酸治疗的患者中，通过分子和临床指标的综合检测，发现了强烈的、剂量依赖性的抗肿瘤作用；与接受 1.7mMα1-油酸治疗的肿瘤中 47%的部分缓解相比，接受 8.5mMα1-油酸治疗的肿瘤中 88%的肿瘤完全或部分缓解。肿瘤对α1-油酸的摄取引发了肿瘤细胞快速脱落到尿液中，并通过类似凋亡的机制导致细胞死亡。组织活检的 RNA 测序证实了凋亡细胞死亡的激活和对癌症基因网络的强烈抑制，包括膀胱癌相关基因。除了在灌注部位有局部刺激外，没有记录到与药物相关的副作用。

讨论和结论

α1-油酸的这些剂量依赖性抗肿瘤作用很有前途，支持了α1-油酸在 NMIBC 患者中的治疗潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d10/11386334/241b0757d8c6/CAM4-13-e70149-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d10/11386334/27ba20ba098c/CAM4-13-e70149-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d10/11386334/60d5d89acbbb/CAM4-13-e70149-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d10/11386334/a32c0e8e42b0/CAM4-13-e70149-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d10/11386334/f5aa6e8a94e3/CAM4-13-e70149-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d10/11386334/a14b9fa1001f/CAM4-13-e70149-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d10/11386334/241b0757d8c6/CAM4-13-e70149-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d10/11386334/27ba20ba098c/CAM4-13-e70149-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d10/11386334/60d5d89acbbb/CAM4-13-e70149-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d10/11386334/a32c0e8e42b0/CAM4-13-e70149-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d10/11386334/f5aa6e8a94e3/CAM4-13-e70149-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d10/11386334/a14b9fa1001f/CAM4-13-e70149-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d10/11386334/241b0757d8c6/CAM4-13-e70149-g003.jpg

相似文献

1
Clinical and molecular response to alpha1-oleate treatment in patients with bladder cancer.α-1-油酸治疗膀胱癌患者的临床和分子反应。
Cancer Med. 2024 Sep;13(17):e70149. doi: 10.1002/cam4.70149.
2
Bladder cancer therapy without toxicity-A dose-escalation study of alpha1-oleate.α-亚麻酸治疗膀胱癌的毒性研究-剂量递增研究。
Int J Cancer. 2020 Nov 1;147(9):2479-2492. doi: 10.1002/ijc.33019. Epub 2020 May 11.
3
Long-term prevention of bladder cancer progression by alpha1-oleate alone or in combination with chemotherapy.单独使用α-亚麻酸或与化疗联合预防膀胱癌进展。
Int J Cancer. 2023 Aug 1;153(3):584-599. doi: 10.1002/ijc.34500. Epub 2023 Apr 3.
4
Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex.使用构象灵活的杀肿瘤肽复合物进行膀胱癌治疗。
Nat Commun. 2021 Jun 8;12(1):3427. doi: 10.1038/s41467-021-23748-y.
5
Similar immune responses to alpha1-oleate and Bacillus Calmette-Guérin treatment in patients with bladder cancer.在膀胱癌患者中，α1-油酸和卡介苗治疗引起的免疫反应相似。
Cancer Med. 2024 Apr;13(7):e7091. doi: 10.1002/cam4.7091.
6
[Mechanism of intravesical instillation of pirarubicin for preventing recurrence of non-muscle invasive bladder cancer].吡柔比星膀胱灌注预防非肌层浸润性膀胱癌复发的机制
Zhonghua Zhong Liu Za Zhi. 2009 Dec;31(12):904-7.
7
Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.低剂量吡柔比星强化灌注与卡介苗治疗高危非肌层浸润性膀胱癌患者的安全性和有效性。
Urol Oncol. 2020 Aug;38(8):684.e17-684.e24. doi: 10.1016/j.urolonc.2020.03.009. Epub 2020 Apr 9.
8
Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation.吡柔比星（THP）单次与两次膀胱灌注用于单发非肌层浸润性膀胱癌术后早期腔内化疗的前瞻性随机对照研究
World J Urol. 2018 Jun;36(6):889-895. doi: 10.1007/s00345-018-2196-8. Epub 2018 Jan 31.
9
Clinical application of drug sensitive gene detection in postoperative instillation for non-muscle invasive bladder cancer.药物敏感基因检测在非肌层浸润性膀胱癌术后灌注中的临床应用。
BMC Nephrol. 2020 Oct 7;21(1):426. doi: 10.1186/s12882-020-02073-4.
10
A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer.一种靶向 HER2 的抗体药物偶联物 RC48-ADC，在膀胱癌的临床前模型中通过膀胱内灌注表现出了良好的抗肿瘤疗效和安全性。
Adv Sci (Weinh). 2023 Nov;10(32):e2302377. doi: 10.1002/advs.202302377. Epub 2023 Oct 12.

引用本文的文献

1
Rapid ER remodeling induced by a peptide-lipid complex in dying tumor cells.一种肽 - 脂质复合物在垂死肿瘤细胞中诱导的内质网快速重塑。
Life Sci Alliance. 2025 Mar 25;8(6). doi: 10.26508/lsa.202403114. Print 2025 Jun.

本文引用的文献

1
Similar immune responses to alpha1-oleate and Bacillus Calmette-Guérin treatment in patients with bladder cancer.在膀胱癌患者中，α1-油酸和卡介苗治疗引起的免疫反应相似。
Cancer Med. 2024 Apr;13(7):e7091. doi: 10.1002/cam4.7091.
2
Long-term prevention of bladder cancer progression by alpha1-oleate alone or in combination with chemotherapy.单独使用α-亚麻酸或与化疗联合预防膀胱癌进展。
Int J Cancer. 2023 Aug 1;153(3):584-599. doi: 10.1002/ijc.34500. Epub 2023 Apr 3.
3
Molecular Subtyping in Muscle-Invasive Bladder Cancer on Predicting Survival and Response of Treatment.
肌肉浸润性膀胱癌的分子分型对生存及治疗反应的预测
Biomedicines. 2022 Dec 27;11(1):69. doi: 10.3390/biomedicines11010069.
4
Calmette-Guérin Treatment Changes the Tumor Microenvironment of Non-Muscle-Invasive Bladder Cancer.卡介苗治疗改变非肌层浸润性膀胱癌的肿瘤微环境。
Front Oncol. 2022 Mar 3;12:842182. doi: 10.3389/fonc.2022.842182. eCollection 2022.
5
Genomic analysis of response to bacillus Calmette-Guérin (BCG) treatment in high-grade stage 1 bladder cancer patients.高级别1期膀胱癌患者对卡介苗（BCG）治疗反应的基因组分析。
Transl Androl Urol. 2021 Jul;10(7):2998-3009. doi: 10.21037/tau-21-158.
6
ALPK2 acts as tumor promotor in development of bladder cancer through targeting DEPDC1A.ALK2 通过靶向 DEPDC1A 作为膀胱癌发展的肿瘤促进剂。
Cell Death Dis. 2021 Jul 1;12(7):661. doi: 10.1038/s41419-021-03947-7.
7
Non-muscle-invasive bladder cancer: An overview of potential new treatment options.非肌肉浸润性膀胱癌：潜在新治疗选择的概述。
Urol Oncol. 2021 Oct;39(10):642-663. doi: 10.1016/j.urolonc.2021.05.015. Epub 2021 Jun 22.
8
Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex.使用构象灵活的杀肿瘤肽复合物进行膀胱癌治疗。
Nat Commun. 2021 Jun 8;12(1):3427. doi: 10.1038/s41467-021-23748-y.
9
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.纳武拉非尼基因导管治疗卡介苗无应答性非肌肉浸润性膀胱癌：一项单臂、开放标签、重复剂量临床试验。
Lancet Oncol. 2021 Jan;22(1):107-117. doi: 10.1016/S1470-2045(20)30540-4. Epub 2020 Nov 27.
10
Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect.BCG 在膀胱癌治疗中的作用机制：当前认识与展望。
Biomed Pharmacother. 2020 Sep;129:110393. doi: 10.1016/j.biopha.2020.110393. Epub 2020 Jun 16.